Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPQAGE)

Drug Name

Mycophenolate mofetil Drug Info

Synonyms

mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)

Indication

Disease Entry	ICD 11	Status	REF
Hepatosplenic T-cell lymphoma		Approved	[1]
Interstitial cystitis	GC00.3	Approved	[1]
Large granular lymphocytic leukemia	2A90.1	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[1]
MALT lymphoma		Approved	[1]
Myeloid leukaemia	2B33.1	Approved	[1]
Myeloproliferative neoplasm	2A20	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Organ transplant rejection	NE84	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified		Approved	[1]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[1]
Small intestine lymphoma		Approved	[1]
Splenic marginal zone lymphoma		Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Testicular lymphoma		Approved	[1]
Pemphigus vulgaris	EB40	Phase 3	[2]
Classic Hodgkin lymphoma		Investigative	[1]
Immune System disease	4A01-4B41	Investigative	[3]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[4]

Therapeutic Class

Immunosuppressive Agents

Cross-matching ID

PubChem CID: 5281078
ChEBI ID: CHEBI:8764
CAS Number: CAS 128794-94-5
TTD Drug ID: DMPQAGE
VARIDT Drug ID: DR00243
INTEDE Drug ID: DR1118
ACDINA Drug ID: D00449

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)	TTTB4UP	IMDH2_HUMAN	Inhibitor	[5]
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	Highest Status	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Approved	[6]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Approved	[7]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Approved	[6]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Approved	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Approved	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Approved	[8]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Approved	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Approved	[8]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Approved	[8]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Approved	[8]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Approved	[10]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Approved	[11]
UDP-glucuronosyltransferase 1A6 (UGT1A6)	DESD26P	UD16_HUMAN	Approved	[9]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Prostaglandin E2 receptor EP2 (PTGER2)	DTT	PTGER2	4.75	5.888	5.066	4.466
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.009	6.988	7.442	8.135
Breast cancer resistance protein (ABCG2)	DTP	BCRP	6.732	7.513	6.326	9.277
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	7.751	4.17	6.425	6.282
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	8.873	2.17	2.485	3.322
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	9.79	0.485	3.511	2.07
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	9.791	3.744	3.413	1.609
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	10.08	7.207	5.403	9.211
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hepatosplenic T-cell lymphoma

ICD Disease Classification

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin E2 receptor EP2 (PTGER2)	DTT	PTGER2	2.77E-06	1.15	1.37
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.96E-01	9.10E-02	1.78E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	3.20E-01	-2.44E-01	-2.70E-01
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	6.57E-01	-7.03E-03	-3.29E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	7.75E-01	3.79E-03	1.43E-02
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	5.94E-01	-5.43E-03	-2.82E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.98E-01	1.01E-01	3.33E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	7.97E-02	-4.55E-02	-3.54E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.74E-03	-6.47E-02	-1.18E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.50E-01	8.27E-02	3.14E-01

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Mycophenolate mofetil FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6831).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
4	High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 May 29;93(12). pii: e00023-19.
5	Clinical pipeline report, company report or official report of Roche (2009).
6	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
7	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
8	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
9	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
10	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
11	[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.